| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Triptonine B targets HIV, exhibiting potent activity against HIV replication. It targets enzymatic active sites or protein interfaces involved in the HIV life cycle. Resistance arises via amino acid substitutions that reduce inhibitor binding affinity. The compound's mechanism of action involves inhibition of HIV replication, though the specific viral target has not been fully elucidated. As a sesquiterpenoid pyridine alkaloid, it may interact with viral enzymes or proteins essential for HIV replication.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Triptonine B is a potent inhibitor of HIV replication. In H9 lymphocytes, the compound inhibits HIV replication with an EC₅0 value of <0.10 microg/mL. The compound exhibits a high therapeutic index of >1000, indicating a favorable selectivity profile. Its in vitro activity is assessed using HIV-infected cell lines, with viral replication measured by p24 antigen production or reverse transcriptase activity. The compound's potency and selectivity make it a promising lead for anti-HIV drug development.
|
| ln Vivo |
In vivo activity of Triptonine B has not been extensively characterized in the available literature. As a potent anti-HIV compound with a high therapeutic index in vitro, the compound has potential for in vivo efficacy. However, detailed in vivo studies, including animal models of HIV infection, are not reported. The compound is primarily used as a research tool for studying anti-HIV activity.
|
| Enzyme Assay |
In vitro antiviral assays for Triptonine B involve measuring its inhibition of HIV replication in susceptible cell lines such as H9 lymphocytes. Cells are infected with HIV and treated with varying concentrations of the compound. Viral replication is quantified by measuring p24 antigen levels in culture supernatants using ELISA or by measuring reverse transcriptase activity. EC₅0 values are calculated from dose-response curves. Cytotoxicity is assessed in parallel to determine the therapeutic index (TI = CC₅0/EC₅0).
|
| Cell Assay |
Cellular assays for Triptonine B are conducted using HIV-susceptible cell lines such as H9 lymphocytes. Cells are infected with HIV-1 and treated with varying concentrations of the compound for 3-7 days. Viral replication is measured by p24 antigen ELISA or reverse transcriptase activity in culture supernatants. Cytotoxicity is assessed using MTT or similar assays to determine the CC₅0. The therapeutic index is calculated as the ratio of CC₅0 to EC₅0. The compound's effects on cell viability and viral replication are compared to control treatments.
|
| Animal Protocol |
In vivo animal studies for Triptonine B are limited, as the compound is primarily used as a research tool. For in vivo efficacy studies, animal models of HIV infection (e.g., humanized mouse models) could be employed. Infected animals would be treated with the compound via oral or intraperitoneal administration at various doses. Viral load would be measured in plasma, and CD4+ T-cell counts would be monitored. However, specific in vivo study protocols and results are not extensively reported in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Triptonine B have not been extensively characterized. The compound has a molecular weight of 967.87 and a molecular formula of C4₆H4₉NO22. It has low aqueous solubility (0.025 g/L at 25degC). The compound is stable when stored as directed on the vial and kept tightly sealed for up to 24 months at 2-8degC. Detailed PK parameters such as half-life, bioavailability, and volume of distribution are not reported in the available literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for Triptonine B are limited. The compound is not intended for human therapeutic use and is supplied for research purposes only. In cell-based assays, the compound exhibits potent anti-HIV activity with a high therapeutic index (>1000), suggesting low cytotoxicity. The compound is derived from Tripterygium wilfordii, a plant known for its toxic components, so caution should be exercised. Standard safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Triptonine B is a natural sesquiterpenoid pyridine alkaloid from Tripterygium wilfordii with potent anti-HIV activity (EC₅0 <0.10 microg/mL). It has a high therapeutic index of >1000. The compound is not an FDA-approved drug and has no clinical indications. It is available in high purity (≥98%) and is typically stored at 2-8degC or -20degC. The compound is used as a research tool for studying anti-HIV activity.
|
| Molecular Formula |
C45H55NO22
|
|---|---|
| Molecular Weight |
961.911700000001
|
| Exact Mass |
961.321
|
| CAS # |
168009-85-6
|
| Appearance |
White to off-white solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1003.3±65.0 °C at 760 mmHg
|
| Flash Point |
560.6±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.580
|
| LogP |
1.51
|
| SMILES |
CC(=O)OC[C@@]12[C@@H]([C@@H](C3[C@H]([C@@]42[C@](C)([C@H]([C@@H]([C@@H]1OC(=O)C)OC(=O)C5=COC=C5)OC(=O)[C@@](C)(CCC6=C(C=CC=N6)C(=O)OC[C@]3(C)O4)OC(=O)C7=COC=C7)O)OC(=O)C)OC(=O)C)OC(=O)C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0396 mL | 5.1980 mL | 10.3960 mL | |
| 5 mM | 0.2079 mL | 1.0396 mL | 2.0792 mL | |
| 10 mM | 0.1040 mL | 0.5198 mL | 1.0396 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
